Intestinal Immunity in Neurologic Disease
Part of paid clinical trials in North Haven, Connecticut.
- Sponsor
- Yale University
- Study ID
- NCT06329453
- Status
- Recruiting
Conditions
- Multiple Sclerosis
- Parkinson Disease
- REM Sleep Behavior Disorder
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 99 Years
- Healthy Volunteers
- Accepted
Interventions
- Colon Tissue Biopsy — PROCEDUREColonoscopy and colon tissue biopsy.
Study Details
The purpose of this study is to ascertain the functional profiles of the immune cells within the gastrointestinal tract and to determine how these cells contribute to autoimmune and neurologic diseases.
Key Dates
- Start date
- Aug 2, 2022
- Status verified
- May 2026
- Primary completion
- Aug 31, 2027
- Completion
- Aug 31, 2027
Study Design
- Enrollment
- 100 participants (estimated)
Arms
- Arm: Healthy Individuals
- Arm: Individuals with neurologic diseases
- Arm: Individuals with known or suspected autoimmune diseases
Primary Outcome Measure
Characterization of immune cells from the gastrointestinal mucosa [ Time Frame: Through study completion, an average of 5 years ]
Central Contacts
- Cynthia Marques2032876100
- Dimitri Duvilaire2032876100
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Yale MS Clinic | North Haven | Connecticut | 06473 | Erin Longbrake, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in North Haven, CT
By condition
By specialty
By research site
Related Studies
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- PPMI Clinical - Establishing a Deeply Phenotyped PD CohortRecruiting · Michael J. Fox Foundation for Parkinson's Research · Birmingham, Alabama
- Ocrelizumab Discontinuation in Relapsing Multiple SclerosisPHASE4 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · New Haven, Connecticut
- A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple SclerosisPHASE1 · Recruiting · Hoffmann-La Roche · Stanford, California